The development pipeline for new drugs and therapies is a long one, and, on average, it can take up to 17 years to research, test, and bring a new product to market . The reasons for this are myriad and complex, and they include the demanding test phases required for safety and efficacy, preclinical tests, regulatory paperwork, and the need to raise funding to pay for the increasingly higher costs of R&D that accompany such projects.
In 2016, a new study of R&D costs estimated the cost of developing a new drug to be $2.558 billion. This figure per approved compound is based on estimated average out-of-pocket costs of $1.395 billion and time costs (expected returns that investors forego while a drug is in development) of $1.163 billion . In short, bringing a new treatment to market is hard; this is why the news about a unique treatment for treating age-related macular degeneration heading to clinical trials is so exciting.
Ichor Therapeutics, a biotechnology company focused on developing drugs for age-related diseases, has just announced its first major series A investment round to bring its LYSOCLEAR product for age-related macular degeneration and Stargardt’s macular degeneration to Phase I clinical trials. This product would be the first clinical candidate based on the SENS paradigm pioneered by biomedical gerontologist Dr. Aubrey de Grey.
About age-related macular degeneration
Age-related macular degeneration (AMD) is the leading cause of vision loss among people over the age of 50. Over 20 million Americans and 450 million people globally  are affected by this condition. 85% of all cases arise from the progressive loss of photoreceptors in the macula – a part of the eye responsible for central vision. The underlying pathology of AMD is thought to be caused by the death of retinal pigmented epithelial (RPE) cells, which photoreceptors in the macula rely upon to feed and survive.
With time, different byproducts are formed that accumulate in the lysosomes of RPE cells (lysosomes are cellular structures responsible for recycling waste) and interfere with their function. One of these aggregates is A2E, a toxic compound that may play a causative role in AMD and SMD.
LYSOCLEAR is an enzyme product that can enter the lysosomes of RPE cells where A2E accumulates and destroy it. Ongoing studies suggest that LYSOCLEAR is safe and effective at targeting A2E, eliminating up to 10% with each dose. Clinical trials will test this new therapy in humans to identify the optimal dose and application regimen.
Ichor is a shining example of our mission to kick-start the rejuvenation biotechnology industry with a project that we initiated with early donor support. Led by one of our most dynamic and accomplished alumni, Kelsey Moody, Ichor is forging ahead faster than we could have dreamed. – Aubrey de Grey
For an outside observer, it may seem that such breakthroughs just happen in an instant. The truth is that there are decades of constant effort behind each event of this scale. Let’s take a short glance at the past.
A bit of background
Dr. Aubrey de Grey proposed a repair approach to treating the diseases of aging back in the 2000s. Methuselah Foundation first attempted to support scientific research on aging in 2003. In its first article, Aubrey introduced his approach to academia, naming it SENS, which stands for Strategies for Engineered Negligible Senescence . SENS divides aging into seven categories of damage (including toxic protein aggregation in lysosomes) and proposes repair therapies for each of them.
By addressing the aging processes one by one, medicine could prevent and treat age-related diseases to hopefully keep people healthy and independent as they grow older. Aubrey has received more than his fair share of criticism during this time; however, he was not one to give in easily. In 2009, he co-founded the SENS Research Foundation to develop the therapies and approaches he proposed. Since then, SRF has been working tirelessly to bring the cutting edge technologies it proposes into being and ultimately to market.
Successful crowdfunding activities allowed SENS to support fundamental research in many directions. Late last year, we saw the first proof of concept for its MitoSENS program aimed at repairing mitochondrial damage with a publication demonstrating that this particular SENS technology could be practical.
The OncoSENS fundraiser in 2016 helped to launch a high-throughput screening of a library of diverse drugs to find treatments for cancers that rely on alternative lengthening of telomeres. These ALT cancers correspond to 15% of all cancers, and there is no cure for them at the moment.
Fundamental research like that promoted by SRF does not directly lead to drug development, but it enriches our knowledge base, helping to find promising candidate drugs and therapies. The next logical step is translation, in which biotech startups bring candidate therapies to clinical trials.
Luckily, as at this stage the end-product can start bringing profit, it is much easier to attract investment for its further development. Last year, biotech company Unity Biotechnology announced $116 million in Series B financing to bring senescent cell clearing therapies into human clinical trials in the next year or so. The SENS Research Foundation supported some of the key researchers behind Unity for many years, as senescent cell clearance is again another SENS therapy and part of its ApoptoSENS approach.
In 2014, Ichor Therapeutics completed a material and technology transfer agreement for rights to the concepts and research pioneered by SENS Research Foundation. Now, Ichor has opened a Series A funding round to support preclinical Investigational New Drug (IND) enabling studies and phase I human clinical trials for AMD and SMD.
The company has established a partnership with Syracuse University and obtained dedicated seed funding for the program from Kizoo Technology Ventures, SENS Research Foundation, FightAging.org, CenterState CEO, and several private investors to support its present work on LYSOCLEAR.
So, things are moving forward, and we are now seeing the first SENS therapies proposed back in the 2000s moving into clinical trials. The timeframe is about right, given the current pace of research. Hopefully, we will see Ichor succeed, as millions of people around the world will be protected against age-related vision impairment caused by AMD and SMD and will be able to live their lives to the fullest for longer. Source: LYSOCLEAR Press Release
 Morris, Z. S., Wooding, S., & Grant, J. (2011). The answer is 17 years, what is the question: understanding time lags in translational research. Journal of the Royal Society of Medicine, 104(12), 510-520.
 DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of health economics, 47, 20-33.
 Mariotti, S. P. Global data on visual impairment 2010. Geneva: World Health Organization; 2012. WHO/NMH/PBD/12.01.
 De Grey, A. D. N. J. (2005). A strategy for postponing aging indefinitely. Studies in health technology and informatics, 118, 209.